Nasdaq: NTLA
Intellia Therapeutics insiders
The officers, directors and 10% owners of Intellia Therapeutics, Inc. who hold the most stock, valued at the live NTLA price.
$9.52
NTLA today −$250K (−2.56%)
Market closed. Prices as of Nov 19, 4:04 PM ET
- Ranked insiders
- 6
- Their NTLA stock
- $17.2M
- Market value
- $1.34B
- Held by ranked insiders
- 1.28%
Insiders by value of NTLA holdings
SEC ownership page| # | Insider | Role | Shares | Value | Of company | Overall rank |
|---|---|---|---|---|---|---|
| 1 | John M. Leonard | President and CEO | 1,196,479 | $11.4M | 0.85% | 6217th |
| 2 | Fred E. Cohen | Director | 216,653 | $2.1M | 0.15% | 6366th |
| 3 | Jing L. Marantz | EVP, Chief Medical Officer | 199,822 | $1.9M | 0.14% | 10139th |
| 4 | William Chase | Director | 143,893 | $1.4M | 0.10% | 12947th |
| 5 | Brian Goff | Director | 32,609 | $310K | <0.1% | 13359th |
| 6 | Caroline Dorsa | Director | 12,701 | $121K | <0.1% | 7384th |
Only insiders worth at least $5 million in listed stock are ranked. Holdings come from each insider's latest Form 3, 4 or 5 for Intellia Therapeutics; see each profile for the filing.